Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata

Alopecia areata (AA) is a common autoimmune disorder. Although its pathogenesis is not fully understood, AA involves CD8 T cell-mediated destruction of the hair follicle. Several treatment options exist; however, there is minimal evidence in the pediatric population. Currently, there are no curative treatments for AA. The literature suggests that Janus kinase (JAK) inhibitors may be an effective treat-ment for AA, but evidence in pediatric patients is limited. Here, we report a case of severe pediatric AA treated with topical ruxolitinib, a JAK inhibitor. J Drugs Dermatol. 2024;23(5):378-379. doi:10.36849/JDD.7782.

Survey of the Prices of Topical Compounded Medications for Alopecia in the Tri-State Area

BACKGROUND

Currently, there is only one topical medication approved by the U.S. Food and Drug Administration for alopecia, minoxidil 2.5% and 5%. With limited options, dermatologists often turn to compounding pharmacies for customized topical alopecia medications.

OBJECTIVES

(1) to investigate the pricing and availabilities of compounded topical alopecia medications and (2) to investigate the delivery/mail options available.

METHODS

103 dermatological compounding pharmacies in the tri-state area were contacted. Data were collected on the prices of 11 different compounded formulations for alopecia, the highest concentration of minoxidil available, compounding accreditation status, and delivery.

RESULTS

The majority (76.7% [79/103]) of pharmacies surveyed were responsive. Mean prices for 60 g or mL of medication were $70.44 for minoxidil 5%, $86.95 for minoxidil 5%/finasteride 0.5%, $159.13 for minoxidil 5%/bimatoprost 0.03%, $141.91 for minoxidil 5%/latanoprost 0.02%, $75.31 for finasteride 0.5%, $204.41 for tacrolimus 0.3%, $220.11 for tacrolimus 0.3%/minoxidil 5%/clobetasol 0.05%, $71.44 for cetirizine 1%, $74.93 for metformin 10%, $4,273.20 for tofacitinib 2%, and $1,840.42 for ruxolitinib 2%. Nearly all (93.5% [72/77]) of the pharmacies reported being able to compound minoxidil higher than the commercially available 5%, while 67.6% (50/74) were able to customize minoxidil to be made with <10% alcohol. Just over half (56.4% [44/78]) of the pharmacies were able to deliver to all tri-state areas. The mean delivery fee of pharmacies was $5.93 (n=77). Almost all of the pharmacies (98.7% [76/77]) claimed to be able to process and deliver medications within a week. If pharmacies were not located in the local vicinity, 44.6% (29/65) used a mailing service.

CONCLUSION

This survey serves to expand clinicians' and patients' knowledge of the options and prices of topical compounded medications for alopecia. J Drugs Dermatol. 2024;23(3):     doi:10.36849/JDD.7697.

Treatment for central centrifugal cicatricial alopecia-Delphi consensus recommendations

BACKGROUND

There is no established standard of care for treating central centrifugal cicatricial alopecia (CCCA), and treatment approaches vary widely.

OBJECTIVE

To develop consensus statements regarding the use of various pharmacological therapies in treating adults with CCCA.

METHODS

We invited 27 dermatologists with expertise in hair and scalp disorders to participate in a 3-round modified Delphi study between January and March 2023. Statements met strong consensus if 75% of respondents agreed or disagreed. Statements met moderate consensus if 55% or more but less than 75% agreed or disagreed.

RESULTS

In round 1, 5 of 33 (15.2%) statements met strong consensus, followed by 9 of 28 (32.1%) in round 2. After the final round 3 meeting, strong consensus was reached for 20 of 70 (28.6%) overall statements. Two statements achieved moderate consensus.

LIMITATIONS

This study included only English-speaking, US-based dermatologists and did not consider nonpharmacological therapies.

CONCLUSION

Despite varying opinions among dermatologists, consensus was reached for several statements to help clinicians manage CCCA. We also highlight areas that lack expert consensus with the goal of advancing research and therapeutic options for CCCA.

Frontal Fibrosing Alopecia Presenting as Androgenetic Alopecia in an African American Woman

Frontal fibrosing alopecia (FFA) is a primary lymphocytic cicatricial alopecia that is currently regarded as a variant of lichen planopilaris. FFA has historically been considered rare in black patients, in whom traction alopecia, central centrifugal cicatricial alopecia, and androgenetic alopecia are frequently assumed to be more common. We describe a case of FFA in a black woman that both clinically resembled androgenetic alopecia and lacked many of the physical exam and dermoscopic findings associated with FFA. In doing so, we highlight the need for physicians to have a high index of suspicion for FFA in any black patient who presents with frontotemporal alopecia. J Drugs Dermatol. 2020;19(7): doi:10.36849/JDD.2020.4682.

Efficacy and Safety of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel for the Treatment of Acne and Acne-induced Post-inflammatory Hyperpigmentation in Patients with Skin of Color

OBJECTIVE

To assess the efficacy and safety of a topical gel containing clindamycin 1.2% and tretinoin 0.025% for the treatment of acne and acne-induced postinflammatory hyperpigmentation (PIH) in darker skinned patients.

DESIGN

Randomized, double-blind, placebo-controlled study.

SETTING

Two United States clinical sites.

PARTICIPANTS

Thirty-three patients 12 years of age or older with skin types IV to VI, mild-to-moderate facial acne, and PIH were enrolled.

MEASUREMENTS

Patients applied clindamycin phosphate/tretinoin gel or a nonmedicated vehicle each evening and a sun protection factor 30 sunscreen daily. Changes in skin erythema and hyperpigmentation were measured using a chromameter and photographic images. Efficacy was assessed using the Evaluators Global Acne Severity Scale, lesion counts, Post-inflammatory Hyperpigmentation Severity Scales and Patient's Global Assessment Scale. Safety and tolerability were assessed by adverse event reports and a Safety Assessment Scale.

RESULTS

The mean (SD) baseline inflammatory lesion count was 11.9 (11.1) in clindamycin/tretinoin-treated patients, decreasing by 5.5 (6.56) after 12 weeks while the mean baseline inflammatory lesion count was 13.6 (11.15) in placebo-treated patients, decreasing by 4.1 (11.36) (p=0.05 for change from baseline, clindamycin/tretinoin vs. placebo). Clindamycin/tretinoin-treated patients generally demonstrated superior efficacy versus placebo treatment. The clindamycin/tretinoin topical gel was well tolerated, causing little or no irritation, although one patient withdrew due to periorbital edema of moderate severity possibly related to clindamycin/tretinoin gel.

CONCLUSION

Although limited by small sample size, the results of this pilot study suggest clindamycin phosphate 1.2% and tretinoin 0.025% topical gel is a safe and effective option for treating mild-to-moderate acne in patients with skin of color.

Comparative evaluation of men's depilatory composition versus razor in black men

Shaving with razors often is problematic for men with sensitive skin, especially black individuals who are generally prone to developing pseudofolliculitis barbae (PFB). For patients with PFB, physicians often recommend shaving with depilatory creams that chemically remove hair from the skin surface by dissolving keratin. This 1-week, controlled, single-center, split-faced, randomized trial compared shaving with 3 different depilatory compositions to shaving with a manual razor in black men. One depilatory composition was withdrawn during the study because of the high incidence of adverse events. The depilatory compositions produced fewer papules and more irritation immediately after use and to a greater extent than the manual razor; the irritation was transient and more often subjective than objective. In this preliminary study, the result of using depilatory compositions was that the skin looked and felt smoother compared to shaving with a razor. Depilatory products are recommended for patients who develop PFB or are unsatisfied with the results of shaving with a manual razor.

Common and uncommon hair and nail problems in sports

We report an exhaustive review of the hair and nail conditions related to participation in sports. It is important that medical professionals who care for athletes recognize the unique dermatologic conditions that may affect those athletes.